# Oxidative stress-mediated responses in endometrial cancer cells: contrasting effects of doxorubicin and menadione

**Authors:** Joanna Kozak, Sandra Tkaczyk–Beraś, Krzysztof Jędraszek

PMC · DOI: 10.3389/fphys.2026.1733194 · 2026-02-02

## TL;DR

The study compares how two endometrial cancer cell lines respond to oxidative and genotoxic stress, highlighting differences in antioxidant defenses.

## Contribution

The research identifies cell line-specific redox responses and highlights potential therapeutic targets in endometrial cancer.

## Key findings

- AN3CA cells are more sensitive to doxorubicin, while KLE cells are more vulnerable to menadione.
- SESN2, SESN3, and SOD1 show biphasic expression patterns under stress.
- mRNA and protein levels of antioxidant genes do not always correlate, suggesting post-transcriptional regulation.

## Abstract

Oxidative stress plays a crucial role in the development and treatment response of endometrial cancer, yet the antioxidant defense mechanisms in different tumor subtypes remain unclear.

We investigated the cellular response to oxidative (menadione) and genotoxic (doxorubicin) stress in two TP53-mutated endometrial cancer cell lines, AN3CA and KLE. Cell viability, reactive oxygen species (ROS) levels, and the expression of antioxidant-related genes (SESN2, SESN3, SOD1) were assessed using qPCR and In-Cell Western assays.

AN3CA cells showed greater sensitivity to doxorubicin, marked by increased ROS and reduced viability, while KLE cells were more susceptible to menadione-induced toxicity. Protein expression analysis revealed a biphasic response: low doses of doxorubicin transiently increased SESN and SOD1 expression, whereas higher doses suppressed them. Gene expression at the mRNA level did not always correlate with protein levels, suggesting possible post-transcriptional regulation.

Our findings demonstrate cell line - specific redox responses and identify SESN2, SESN3, and SOD1 as key players in the antioxidant defense network. These genes may serve as potential therapeutic targets in aggressive, hormone-independent endometrial cancers.

## Linked entities

- **Genes:** TP53 (tumor protein p53) [NCBI Gene 7157], SESN2 (sestrin 2) [NCBI Gene 83667], SESN3 (sestrin 3) [NCBI Gene 143686], SOD1 (superoxide dismutase 1) [NCBI Gene 6647]
- **Chemicals:** doxorubicin (PubChem CID 31703), menadione (PubChem CID 4055)
- **Diseases:** endometrial cancer (MONDO:0002447)

## Full-text entities

- **Genes:** SESN3 (sestrin 3) [NCBI Gene 143686] {aka SEST3}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, SESN2 (sestrin 2) [NCBI Gene 83667] {aka HI95, SES2, SEST2}
- **Diseases:** tumor (MESH:D009369), toxicity (MESH:D064420), endometrial cancer (MESH:D016889)
- **Chemicals:** menadione (MESH:D024483), doxorubicin (MESH:D004317), ROS (MESH:D017382)

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12907210/full.md

---
Source: https://tomesphere.com/paper/PMC12907210